AXIM Biotechnologies, Inc. (AXIM)
USD 0.0
(17.65%)
USD 0.0
(17.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.77 Million USD | 30.33% |
| 2022 | 9.03 Million USD | 17.96% |
| 2021 | 7.66 Million USD | -21.41% |
| 2020 | 9.74 Million USD | 15.34% |
| 2019 | 8.45 Million USD | 3.44% |
| 2018 | 8.17 Million USD | -3.6% |
| 2017 | 8.47 Million USD | 121.86% |
| 2016 | 3.82 Million USD | 29.22% |
| 2015 | 2.95 Million USD | 124.14% |
| 2014 | 1.31 Million USD | 775.14% |
| 2013 | 150.74 Thousand USD | 9.61% |
| 2012 | 137.52 Thousand USD | 121.45% |
| 2011 | 62.1 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 13.26 Million USD | 16.51% |
| 2024 Q1 | 11.38 Million USD | -3.36% |
| 2023 FY | 11.77 Million USD | 30.33% |
| 2023 Q2 | 13.99 Million USD | 37.17% |
| 2023 Q4 | 11.77 Million USD | 17.79% |
| 2023 Q3 | 9.99 Million USD | -28.56% |
| 2023 Q1 | 10.2 Million USD | 12.91% |
| 2022 Q3 | 8.85 Million USD | 7.33% |
| 2022 FY | 9.03 Million USD | 17.96% |
| 2022 Q4 | 9.03 Million USD | 2.01% |
| 2022 Q1 | 8.48 Million USD | 10.79% |
| 2022 Q2 | 8.25 Million USD | -2.76% |
| 2021 Q3 | 9.6 Million USD | 3.06% |
| 2021 Q4 | 7.66 Million USD | -20.19% |
| 2021 Q1 | 9.63 Million USD | -1.11% |
| 2021 Q2 | 9.31 Million USD | -3.37% |
| 2021 FY | 7.66 Million USD | -21.41% |
| 2020 FY | 9.74 Million USD | 15.34% |
| 2020 Q1 | 11.27 Million USD | 33.41% |
| 2020 Q2 | 10.07 Million USD | -10.68% |
| 2020 Q3 | 9.84 Million USD | -2.29% |
| 2020 Q4 | 9.74 Million USD | -0.94% |
| 2019 Q4 | 8.45 Million USD | -1.19% |
| 2019 FY | 8.45 Million USD | 3.44% |
| 2019 Q2 | 9.04 Million USD | 8.89% |
| 2019 Q1 | 8.3 Million USD | 1.63% |
| 2019 Q3 | 8.55 Million USD | -5.4% |
| 2018 Q3 | 6.99 Million USD | -8.61% |
| 2018 FY | 8.17 Million USD | -3.6% |
| 2018 Q4 | 8.17 Million USD | 16.82% |
| 2018 Q2 | 7.65 Million USD | -11.53% |
| 2018 Q1 | 8.65 Million USD | 2.06% |
| 2017 FY | 8.47 Million USD | 121.86% |
| 2017 Q2 | 7.84 Million USD | 110.79% |
| 2017 Q3 | 8.17 Million USD | 4.23% |
| 2017 Q4 | 8.47 Million USD | 3.7% |
| 2017 Q1 | 3.72 Million USD | -2.62% |
| 2016 Q4 | 3.82 Million USD | -14.48% |
| 2016 Q2 | 3.29 Million USD | 1.99% |
| 2016 Q1 | 3.23 Million USD | 9.36% |
| 2016 FY | 3.82 Million USD | 29.22% |
| 2016 Q3 | 4.46 Million USD | 35.47% |
| 2015 Q3 | 2.58 Million USD | 14.44% |
| 2015 Q4 | 2.95 Million USD | 14.27% |
| 2015 Q2 | 2.26 Million USD | 75.65% |
| 2015 Q1 | 1.28 Million USD | -2.42% |
| 2015 FY | 2.95 Million USD | 124.14% |
| 2014 Q1 | 57.5 Thousand USD | -61.85% |
| 2014 Q4 | 1.31 Million USD | 5.44% |
| 2014 Q3 | 1.25 Million USD | 2174.71% |
| 2014 Q2 | 55 Thousand USD | -4.35% |
| 2014 FY | 1.31 Million USD | 775.14% |
| 2013 FY | 150.74 Thousand USD | 9.61% |
| 2013 Q4 | 150.74 Thousand USD | 6.24% |
| 2013 Q3 | 141.88 Thousand USD | 3.83% |
| 2013 Q1 | 136.13 Thousand USD | -1.01% |
| 2013 Q2 | 136.65 Thousand USD | 0.38% |
| 2012 Q4 | 137.52 Thousand USD | 145.27% |
| 2012 Q3 | 56.07 Thousand USD | 14.85% |
| 2012 FY | 137.52 Thousand USD | 121.45% |
| 2012 Q1 | 77.36 Thousand USD | 24.57% |
| 2012 Q2 | 48.82 Thousand USD | -36.89% |
| 2011 Q4 | 62.1 Thousand USD | 1414.63% |
| 2011 Q3 | 4100.00 USD | 0.0% |
| 2011 FY | 62.1 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -42834.404% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -24.427% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 83.748% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1356.266% |
| Rebus Holdings, Inc. | 5.24 Million USD | -124.689% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 80.042% |
| Qrons Inc. | 1.48 Million USD | -691.166% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -860.534% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 84.279% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -26251.788% |
| Skye Bioscience, Inc. | 14.07 Million USD | 16.302% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 77.904% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -22.92% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2693.902% |
| SQZ Biotechnologies Company | 50.03 Million USD | 76.462% |
| Intellipharmaceutics International Inc. | 12 Million USD | 1.92% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -205.814% |
| Mesoblast Limited | 188.44 Million USD | 93.75% |
| Marizyme, Inc. | 26.67 Million USD | 55.847% |
| Genus plc | 485 Million USD | 97.572% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -101.591% |
| Pharming Group N.V. | 244.07 Million USD | 95.174% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -485.942% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -368.071% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -209.953% |
| ContraFect Corporation | 32.53 Million USD | 63.794% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -494.466% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -207.714% |
| IMV Inc. | 37.93 Million USD | 68.95% |
| MultiCell Technologies, Inc. | 1617.67 USD | -727996.274% |
| ONE Bio Corp. | 27.49 Million USD | 57.164% |
| Accustem Sciences Inc. | 1.07 Million USD | -991.343% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 84.786% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -456.87% |
| Q BioMed Inc. | 8.13 Million USD | -44.821% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 85.798% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -128.879% |
| Biomind Labs Inc. | 1.49 Million USD | -685.94% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 90.079% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -30.258% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 36.0% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -721.432% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8188.958% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5756.419% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -104.987% |
| GB Sciences, Inc. | 5.41 Million USD | -117.408% |
| Alpha Cognition Inc. | 7.16 Million USD | -64.39% |
| HST Global, Inc. | 593.59 Thousand USD | -1884.221% |
| CSL Limited | 18.62 Billion USD | 99.937% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -835.376% |
| Halberd Corporation | 728.71 Thousand USD | -1516.288% |
| Enzolytics Inc. | 365.26 Million USD | 96.775% |
| Agentix Corp. | 2.51 Million USD | -369.147% |
| Resverlogix Corp. | 67.39 Million USD | 82.524% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1304.286% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.353% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -587.176% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 52.404% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 1.049% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -221.355% |
| AVAX Technologies, Inc. | 3.99 Million USD | -194.916% |
| Zenith Capital Corp. | 27.56 Thousand USD | -42622.605% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.112% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4835.26% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -215.405% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1629.966% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -334.357% |
| Kadimastem Ltd | 3.5 Million USD | -236.053% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -17498.044% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 76.567% |
| BioStem Technologies, Inc. | 15.9 Million USD | 25.945% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2434.586% |
| LadRx Corporation | 2.2 Million USD | -435.244% |
| Cell Source, Inc. | 15.8 Million USD | 25.486% |
| Regen BioPharma, Inc. | 5.45 Million USD | -115.812% |
| Regen BioPharma, Inc. | 5.45 Million USD | -115.812% |
| NovAccess Global Inc. | 7.86 Million USD | -49.836% |
| Affymax, Inc. | 8.87 Million USD | -32.772% |
| Itoco Inc. | 1.65 Million USD | -612.469% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -474.108% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -94.713% |
| Mobile Lads Corp. | 1.31 Million USD | -796.705% |
| CytoDyn Inc. | 127.89 Million USD | 90.791% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -28078.174% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -651.939% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -6.635% |
| SYBLEU INC | 681.41 Thousand USD | -1628.496% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -93.025% |
| International Stem Cell Corporation | 5.27 Million USD | -123.199% |
| Bioxytran, Inc. | 3.24 Million USD | -262.462% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1782.075% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -155.098% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 71.27% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 47.1% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -481.528% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -115.009% |
| Neutra Corp. | 973.52 Thousand USD | -1109.845% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 59.407% |
| PureTech Health plc | 125.58 Million USD | 90.621% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -213.49% |
| IXICO plc | 1.9 Million USD | -519.81% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 42.627% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.601% |
| CSL Limited | 18.62 Billion USD | 99.937% |
| Cellectis S.A. | 249.36 Million USD | 95.277% |